Skip to main content

ALBANY MOLECULAR Value Stock - Dividend - Research Selection


ISIN: US0124231095, WKN: 918849

Market price date: 30.11.-0001
Market price: 0,00 USD

ALBANY MOLECULAR Fundamental data and company key figures of the share

Annual reports in USD
Key figures 16-03-2017
Cash flow
Net operating cash flow 26.635.000
Capital Expenditures -52.000.000
Free cash flow -25.365.000
Balance sheet
Total Equity 298.982.000
Liabilities & Shareholders equity 1.209.650.000
Income statement
Net income -70.171.000
Eps (diluted) -1,830
Diluted shares outstanding 38.304.000
Net sales/revenue 570.450.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization832.728.960,00 USD
Raw Data Source
Stock Split

Description of the company

Albany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,